Platinum-resistant Ovarian Cancer Terminated Phase 1 / 2 Trials for Temozolomide (DB00853)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04851834NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade GliomaTreatment